Preventive Vaccine Market Size, Trends and Insights By Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit, Conjugate Vaccines, Others), By Disease Indication (Influenza, Hepatitis, Polio, Measles , Mumps, Rubella (MMR), Others), By Age Group (Pediatric Vaccines, Adult Vaccines), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032


Report Code: CMI35618

Published Date: December 2023

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 2%
87.90B
2022
88.29B
2023
94.75B
2032

Source: CMI

Study Period: 2023-2032
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Sanofi
  • Johnson & Johnson
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

Global Preventive Vaccine Market is anticipated to experience significant growth from 2023 to 2032, driven by factors such as increasing awareness about preventive healthcare, advancements in vaccine development technologies, and the rising prevalence of infectious diseases worldwide.

The market is expected to achieve a Compound Annual Growth Rate (CAGR) of approximately 2% during this period. In 2023, the market is estimated to be valued at USD 88.29 Billion, and it is projected to reach USD 94.75 Billion by 2032.

Preventive vaccines play a crucial role in controlling the spread of infectious diseases and preventing outbreaks.

The market’s growth is influenced by several factors, including:

  • Global Immunization Initiatives: Ongoing global initiatives and vaccination programs, led by organizations such as the World Health Organization (WHO) and Gavi, the Vaccine Alliance, play a pivotal role in promoting vaccination and expanding access to preventive vaccines. These initiatives contribute to increased awareness and uptake of vaccines globally.
  • Technological Advancements in Vaccine Development: Advances in vaccine development technologies, including recombinant DNA technology, mRNA-based vaccines, and vector-based vaccines, have led to the development of more effective and targeted preventive vaccines. Continuous innovation enhances the efficacy, safety, and scalability of vaccines.
  • Rising Incidence of Infectious Diseases: The increasing prevalence of infectious diseases, such as influenza, hepatitis, polio, measles, and others, drives the demand for preventive vaccines. Vaccination is a cost-effective and efficient strategy for preventing and controlling infectious disease outbreaks.
  • Expanding Pediatric Vaccination Programs: Growing emphasis on pediatric vaccination programs, both in developed and developing countries, fuels the demand for preventive vaccines. Governments and healthcare organizations focus on immunizing children against a range of diseases, leading to increased market opportunities.
  • Government Support and Funding: Government support, funding, and incentives for vaccine development and vaccination programs contribute significantly to the growth of the preventive vaccine market. Public-private partnerships play a key role in facilitating vaccine research, production, and distribution.
  • Increasing Adoption of Adult Vaccination: The expanding adoption of preventive vaccines among adults, especially for diseases such as influenza, pneumonia, and human papillomavirus (HPV), drives market growth. The awareness of the importance of adult vaccination in preventing infectious diseases is on the rise.
  • Emerging Infectious Disease Threats: The emergence of new infectious disease threats, such as novel viruses or strains, highlights the need for rapid vaccine development and deployment. The market responds to the dynamic nature of infectious diseases, driving research and innovation in preventive vaccines.
  • Global Health Security Concerns: Concerns related to global health security, including the potential for pandemics, create a heightened awareness of the importance of preventive vaccines. Governments and international organizations prioritize investments in vaccine development to enhance preparedness for public health emergencies.
  • Increasing Healthcare Expenditure: The overall growth in healthcare expenditure, coupled with the prioritization of preventive healthcare measures, contributes to the expansion of the preventive vaccine market. Healthcare systems recognize the long-term cost-effectiveness of vaccination in preventing disease-related healthcare expenses.
  • Population Growth and Urbanization: Population growth and urbanization trends contribute to the increased risk of infectious disease transmission. Preventive vaccines become essential tools in mitigating the impact of infectious diseases in densely populated urban areas, driving market demand.
  • Improving Vaccine Access in Low-Income Countries: Efforts to improve vaccine access in low-income countries through initiatives like the COVAX facility contribute to market growth. The goal of achieving equitable access to preventive vaccines globally fosters collaboration among stakeholders.

Global Preventive Vaccine Market – Mergers and Acquisitions

Pfizer’s Acquisition of BioNTech (2020):

  • Pfizer, a leading pharmaceutical company, acquired BioNTech, a biotechnology company specializing in mRNA vaccine technology.
  • The acquisition aimed to strengthen Pfizer’s position in the vaccine market, particularly in the development and production of mRNA-based vaccines, as exemplified by the successful collaboration on the COVID-19 vaccine.

GlaxoSmithKline’s Partnership with Bharat Biotech (2021):

  • GlaxoSmithKline (GSK) collaborated with Bharat Biotech, an Indian vaccine manufacturer, to develop and manufacture a novel malaria vaccine.
  • The partnership focused on leveraging GSK’s vaccine adjuvant technology to enhance the effectiveness of Bharat Biotech’s malaria vaccine candidate, addressing a significant global health challenge.

Johnson & Johnson’s Acquisition of Novavax (2018):

  • Johnson & Johnson acquired Novavax, a biotechnology company specializing in vaccine development.
  • The acquisition aimed to strengthen Johnson & Johnson’s vaccine portfolio and enhance its capabilities in developing vaccines for respiratory infections, including respiratory syncytial virus (RSV) and influenza.

Sanofi’s Merger with CSL Limited’s Influenza Vaccines Business (2022):

  • Sanofi, a global pharmaceutical company, merged with CSL Limited’s influenza vaccines business.
  • The merger aimed to create a leading global influenza vaccines business, combining Sanofi’s expertise in vaccine development with CSL Limited’s manufacturing capabilities.

AstraZeneca’s Collaboration with Serum Institute of India (2019):

  • AstraZeneca collaborated with Serum Institute of India, one of the world’s largest vaccine manufacturers.
  • The collaboration focused on the development and production of the COVID-19 vaccine, with the Serum Institute of India playing a crucial role in manufacturing and distributing the vaccine globally.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Preventive Vaccine Market Gene Synthesis Market Respiratory Syncytial Virus Vaccine Market
CAGR 2% (Approx) CAGR 19% (Approx) CAGR 4.6% (Approx)
USD 94.75 Billion by 2032 USD 5,879 Million by 2032 USD 2.2 Billion by 2032

Challenges Impacting the Preventive Vaccine Market:

  • Vaccine Hesitancy and Misinformation:  Despite the proven efficacy of vaccines, vaccine hesitancy, fueled by misinformation and mistrust, poses a significant challenge. Public concerns about vaccine safety and efficacy can lead to reduced vaccination rates.
  • Storage and Distribution Logistics: Some vaccines, especially those requiring cold chain storage, face challenges related to storage and distribution logistics. Maintaining the integrity of vaccines during transportation is essential, especially in remote or resource-limited areas.
  • Research and Development Costs: The high costs associated with vaccine research and development can be a barrier for manufacturers. Balancing the need for innovation with cost-effectiveness is essential for sustainable vaccine development.
  • Regulatory Approval and Compliance: Obtaining regulatory approvals for new vaccines and ensuring compliance with stringent regulatory standards are critical challenges. The regulatory landscape requires careful navigation to bring vaccines to market efficiently.
  • Global Vaccine Supply Chain Vulnerabilities: The global vaccine supply chain is vulnerable to disruptions, as seen during the COVID-19 pandemic. Strengthening the resilience of the vaccine supply chain is essential for ensuring continuous access to preventive vaccines.
  • Production Capacity Constraints: Meeting the global demand for preventive vaccines requires substantial production capacity. Increasing production capacity while maintaining quality standards is a complex challenge for vaccine manufacturers.
  • Adaptation to Emerging Variants: The ongoing evolution of infectious disease variants, such as those of the influenza virus, requires continuous adaptation of preventive vaccines. Rapid response capabilities are essential to address emerging threats effectively.
  • Vaccine Affordability and Accessibility: Ensuring the affordability and accessibility of vaccines, particularly in low-income countries, is a persistent challenge. Collaborative efforts are needed to address economic barriers to vaccine access.
  • Ethical Considerations in Clinical Trials: Conducting ethical clinical trials for preventive vaccines involves navigating complex considerations, including informed consent, participant diversity, and transparency. Ethical standards must be upheld throughout the research and development process.
  • Public Health Infrastructure: Strengthening public health infrastructure, including vaccination programs and surveillance systems, is crucial for the effective implementation of preventive vaccines. Investment in healthcare infrastructure is essential for achieving broader vaccine coverage.
  • Post-Vaccination Monitoring and Surveillance: Monitoring the long-term safety and efficacy of preventive vaccines requires robust post-vaccination surveillance systems. Continuous monitoring helps detect and address any potential adverse events.
  • Market Fragmentation and Competition: The preventive vaccine market features multiple players and diverse technologies, leading to market fragmentation. Increased competition necessitates differentiation and innovation among vaccine manufacturers.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 88.29 Billion
Projected Market Size in 2032 USD 94.75 Billion
Market Size in 2022 USD 87.90 Billion
CAGR Growth Rate 2% CAGR
Base Year 2022
Forecast Period 2023-2032
Key Segment By Type, Disease Indication, Age Group and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Segmentation Analysis of the Preventive Vaccine Market:

Type:

  • Inactivated Vaccines: Vaccines containing killed pathogens or inactivated toxins.
  • Live Attenuated Vaccines: Vaccines with weakened live pathogens.
  • Subunit, Conjugate Vaccines: Vaccines using fragments of pathogens or conjugated antigens.
  • Others: Diverse vaccine types, including DNA vaccines and mRNA vaccines.

Global Preventive Vaccine Market 2023–2032 (By Billion)

www.custommarketinsight.com

Disease Indication:

  • Influenza: Vaccines targeting influenza viruses.
  • Hepatitis: Vaccines preventing hepatitis infections.
  • Polio: Vaccines for poliovirus prevention.
  • Measles, Mumps, and Rubella (MMR): Combined vaccines for these diseases.
  • Others: Vaccines for diseases such as diphtheria, tetanus, and pertussis.

Age Group:

  • Pediatric Vaccines: Vaccines for children.
  • Adult Vaccines: Vaccines for adults, including booster shots.

Global Preventive Vaccine Market 2023–2032 (By Age Group)

www.custommarketinsight.com

Preventive Vaccine Market – Regional Analysis:

North America

Market Dynamics:

  • North America, led by the United States, is a prominent market for preventive vaccines with a well-established healthcare infrastructure.
  • The region experiences a high awareness of preventive healthcare, driving vaccination programs and research initiatives.

Key Factors:

  • Strong government support for vaccination programs.
  • Research and development collaborations with leading pharmaceutical companies.
  • Advanced healthcare systems and immunization awareness.

Market Outlook:

  • The North American preventive vaccine market is expected to continue growing, driven by ongoing research and development, public health initiatives, and the introduction of new vaccines.

Europe

Market Dynamics:

  • Europe, with countries like the United Kingdom and Germany, has a mature market for preventive vaccines.
  • The region emphasizes vaccination as a key component of public health strategies, leading to high vaccination coverage.

Key Factors:

  • Established regulatory frameworks for vaccine approvals.
  • Public health campaigns promoting vaccination.
  • Research collaborations and funding for vaccine development.

Market Outlook:

  • The European preventive vaccine market is poised for steady growth, driven by sustained efforts in research, development, and immunization programs.

Asia-Pacific

Market Dynamics:

  • Asia-Pacific, including China and India, represents a growing market for preventive vaccines due to increasing healthcare awareness.
  • The region witnesses a rising focus on expanding vaccination coverage and addressing infectious disease challenges.

Key Factors:

  • Expanding population and urbanization trends.
  • Government initiatives to improve vaccination accessibility.
  • Collaborations with global vaccine manufacturers.

Market Outlook:

  • Asia-Pacific is expected to be a key growth region for preventive vaccines, driven by population health initiatives, increasing disease awareness, and strategic partnerships.

Latin America

Market Dynamics:

  • Latin America is an emerging market for preventive vaccines, experiencing a growing demand for immunization against infectious diseases.
  • The region focuses on strengthening vaccination programs and addressing healthcare disparities.

Key Factors:

  • Government initiatives for vaccine inclusion in public health programs.
  • Partnerships with international organizations for vaccine distribution.
  • Increasing awareness of preventive healthcare measures.

Market Outlook:

  • Latin America is expected to witness growth in preventive vaccine adoption, driven by ongoing efforts to enhance vaccination infrastructure and accessibility.

Middle East and Africa

Market Dynamics:

  • The Middle East and Africa are witnessing increased interest in preventive vaccines, driven by healthcare infrastructure development and disease prevention initiatives.
  • The market is influenced by efforts to combat infectious diseases and promote public health.

Key Factors:

  • Investments in healthcare infrastructure and vaccination programs.
  • Partnerships with global health organizations for vaccine access.
  • Preventive measures against vaccine-preventable diseases.

Market Outlook:

  • The Middle East and Africa are poised for gradual growth in the preventive vaccine market, with a focus on expanding vaccination coverage and addressing healthcare challenges.

Global Preventive Vaccine Market 2023–2032 (By Type)

www.custommarketinsight.com

List of the prominent players in the Preventive Vaccine Market:

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Sanofi
  • Johnson & Johnson
  • Novartis International AG
  • CSL Limited
  • Emergent BioSolutions Inc.
  • AstraZeneca
  • Bharat Biotech
  • Moderna Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • BioNTech SE
  • Daiichi Sankyo Company Limited
  • Others

The Preventive Vaccine Market is segmented as follows:

By Type

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Subunit
  • Conjugate Vaccines
  • Others

By Disease Indication

  • Influenza
  • Hepatitis
  • Polio
  • Measles
  • Mumps, and Rubella (MMR)
  • Others

By Age Group

  • Pediatric Vaccines
  • Adult Vaccines

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Preventive Vaccine Market, (2023 – 2032) (USD Billion)
    • 2.2 Global Preventive Vaccine Market: snapshot
  • Chapter 3. Global Preventive Vaccine Market – Industry Analysis
    • 3.1 Preventive Vaccine Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Global Immunization Initiatives
      • 3.2.2 Technological Advancements in Vaccine Development
      • 3.2.3 Rising Incidence of Infectious Diseases
      • 3.2.4 Expanding Pediatric Vaccination Programs
      • 3.2.5 Government Support and Funding
      • 3.2.6 Increasing Adoption of Adult Vaccination
      • 3.2.7 Emerging Infectious Disease Threats
      • 3.2.8 Global Health Security Concerns
      • 3.2.9 Increasing Healthcare Expenditure
      • 3.2.10 Population Growth and Urbanization
      • 3.2.11 Improving Vaccine Access in Low-Income Countries.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Type
      • 3.7.2 Market Attractiveness Analysis By Disease Indication
      • 3.7.3 Market Attractiveness Analysis By Age Group
  • Chapter 4. Global Preventive Vaccine Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Preventive Vaccine Market: Company Market Share, 2022
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, collaboration, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Preventive Vaccine Market – Type Analysis
    • 5.1 Global Preventive Vaccine Market Overview: By Type
      • 5.1.1 Global Preventive Vaccine Market Share, By Type, 2022 and 2032
    • 5.2 Inactivated Vaccines
      • 5.2.1 Global Preventive Vaccine Market by Inactivated Vaccines, 2023 – 2032 (USD Billion)
    • 5.3 Live Attenuated Vaccines
      • 5.3.1 Global Preventive Vaccine Market by Live Attenuated Vaccines, 2023 – 2032 (USD Billion)
    • 5.4 Subunit
      • 5.4.1 Global Preventive Vaccine Market by Subunit, 2023 – 2032 (USD Billion)
    • 5.5 Conjugate Vaccines
      • 5.5.1 Global Preventive Vaccine Market by Conjugate Vaccines, 2023 – 2032 (USD Billion)
    • 5.6 Others
      • 5.6.1 Global Preventive Vaccine Market by Others, 2023 – 2032 (USD Billion)
  • Chapter 6. Global Preventive Vaccine Market – Disease Indication Analysis
    • 6.1 Global Preventive Vaccine Market Overview: By Disease Indication
      • 6.1.1 Global Preventive Vaccine Market Share, By Disease Indication, 2022 and 2032
    • 6.2 Influenza
      • 6.2.1 Global Preventive Vaccine Market by Influenza, 2023 – 2032 (USD Billion)
    • 6.3 Hepatitis
      • 6.3.1 Global Preventive Vaccine Market by Hepatitis, 2023 – 2032 (USD Billion)
    • 6.4 Polio
      • 6.4.1 Global Preventive Vaccine Market by Polio, 2023 – 2032 (USD Billion)
    • 6.5 Measles
      • 6.5.1 Global Preventive Vaccine Market by Measles, 2023 – 2032 (USD Billion)
    • 6.6 Mumps, and Rubella (MMR)
      • 6.6.1 Global Preventive Vaccine Market by Mumps, and Rubella (MMR), 2023 – 2032 (USD Billion)
    • 6.7 Others
      • 6.7.1 Global Preventive Vaccine Market by Others, 2023 – 2032 (USD Billion)
  • Chapter 7. Global Preventive Vaccine Market – Age Group Analysis
    • 7.1 Global Preventive Vaccine Market Overview: By Age Group
      • 7.1.1 Global Preventive Vaccine Market Share, By Age Group, 2022 and 2032
    • 7.2 Pediatric Vaccines
      • 7.2.1 Global Preventive Vaccine Market by Pediatric Vaccines, 2023 – 2032 (USD Billion)
    • 7.3 Adult Vaccines
      • 7.3.1 Global Preventive Vaccine Market by Adult Vaccines, 2023 – 2032 (USD Billion)
  • Chapter 8. Preventive Vaccine Market – Regional Analysis
    • 8.1 Global Preventive Vaccine Market Regional Overview
    • 8.2 Global Preventive Vaccine Market Share, by Region, 2022 & 2032 (USD Billion)
    • 8.3. North America
      • 8.3.1 North America Preventive Vaccine Market, 2023 – 2032 (USD Billion)
        • 8.3.1.1 North America Preventive Vaccine Market, by Country, 2023 – 2032 (USD Billion)
    • 8.4 North America Preventive Vaccine Market, by Type, 2023 – 2032
      • 8.4.1 North America Preventive Vaccine Market, by Type, 2023 – 2032 (USD Billion)
    • 8.5 North America Preventive Vaccine Market, by Disease Indication, 2023 – 2032
      • 8.5.1 North America Preventive Vaccine Market, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.6 North America Preventive Vaccine Market, by Age Group, 2023 – 2032
      • 8.6.1 North America Preventive Vaccine Market, by Age Group, 2023 – 2032 (USD Billion)
    • 8.7. Europe
      • 8.7.1 Europe Preventive Vaccine Market, 2023 – 2032 (USD Billion)
        • 8.7.1.1 Europe Preventive Vaccine Market, by Country, 2023 – 2032 (USD Billion)
    • 8.8 Europe Preventive Vaccine Market, by Type, 2023 – 2032
      • 8.8.1 Europe Preventive Vaccine Market, by Type, 2023 – 2032 (USD Billion)
    • 8.9 Europe Preventive Vaccine Market, by Disease Indication, 2023 – 2032
      • 8.9.1 Europe Preventive Vaccine Market, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.10 Europe Preventive Vaccine Market, by Age Group, 2023 – 2032
      • 8.10.1 Europe Preventive Vaccine Market, by Age Group, 2023 – 2032 (USD Billion)
    • 8.11. Asia Pacific
      • 8.11.1 Asia Pacific Preventive Vaccine Market, 2023 – 2032 (USD Billion)
        • 8.11.1.1 Asia Pacific Preventive Vaccine Market, by Country, 2023 – 2032 (USD Billion)
    • 8.12 Asia Pacific Preventive Vaccine Market, by Type, 2023 – 2032
      • 8.12.1 Asia Pacific Preventive Vaccine Market, by Type, 2023 – 2032 (USD Billion)
    • 8.13 Asia Pacific Preventive Vaccine Market, by Disease Indication, 2023 – 2032
      • 8.13.1 Asia Pacific Preventive Vaccine Market, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.14 Asia Pacific Preventive Vaccine Market, by Age Group, 2023 – 2032
      • 8.14.1 Asia Pacific Preventive Vaccine Market, by Age Group, 2023 – 2032 (USD Billion)
    • 8.15. Latin America
      • 8.15.1 Latin America Preventive Vaccine Market, 2023 – 2032 (USD Billion)
        • 8.15.1.1 Latin America Preventive Vaccine Market, by Country, 2023 – 2032 (USD Billion)
    • 8.16 Latin America Preventive Vaccine Market, by Type, 2023 – 2032
      • 8.16.1 Latin America Preventive Vaccine Market, by Type, 2023 – 2032 (USD Billion)
    • 8.17 Latin America Preventive Vaccine Market, by Disease Indication, 2023 – 2032
      • 8.17.1 Latin America Preventive Vaccine Market, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.18 Latin America Preventive Vaccine Market, by Age Group, 2023 – 2032
      • 8.18.1 Latin America Preventive Vaccine Market, by Age Group, 2023 – 2032 (USD Billion)
    • 8.19. The Middle-East and Africa
      • 8.19.1 The Middle-East and Africa Preventive Vaccine Market, 2023 – 2032 (USD Billion)
        • 8.19.1.1 The Middle-East and Africa Preventive Vaccine Market, by Country, 2023 – 2032 (USD Billion)
    • 8.20 The Middle-East and Africa Preventive Vaccine Market, by Type, 2023 – 2032
      • 8.20.1 The Middle-East and Africa Preventive Vaccine Market, by Type, 2023 – 2032 (USD Billion)
    • 8.21 The Middle-East and Africa Preventive Vaccine Market, by Disease Indication, 2023 – 2032
      • 8.21.1 The Middle-East and Africa Preventive Vaccine Market, by Disease Indication, 2023 – 2032 (USD Billion)
    • 8.22 The Middle-East and Africa Preventive Vaccine Market, by Age Group, 2023 – 2032
      • 8.22.1 The Middle-East and Africa Preventive Vaccine Market, by Age Group, 2023 – 2032 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1 Pfizer Inc.
      • 9.1.1 Overview
      • 9.1.2 Financials
      • 9.1.3 Product Portfolio
      • 9.1.4 Business Strategy
      • 9.1.5 Recent Developments
    • 9.2 GlaxoSmithKline plc
      • 9.2.1 Overview
      • 9.2.2 Financials
      • 9.2.3 Product Portfolio
      • 9.2.4 Business Strategy
      • 9.2.5 Recent Developments
    • 9.3 Merck & Co. Inc.
      • 9.3.1 Overview
      • 9.3.2 Financials
      • 9.3.3 Product Portfolio
      • 9.3.4 Business Strategy
      • 9.3.5 Recent Developments
    • 9.4 Sanofi
      • 9.4.1 Overview
      • 9.4.2 Financials
      • 9.4.3 Product Portfolio
      • 9.4.4 Business Strategy
      • 9.4.5 Recent Developments
    • 9.5 Johnson & Johnson
      • 9.5.1 Overview
      • 9.5.2 Financials
      • 9.5.3 Product Portfolio
      • 9.5.4 Business Strategy
      • 9.5.5 Recent Developments
    • 9.6 Novartis International AG
      • 9.6.1 Overview
      • 9.6.2 Financials
      • 9.6.3 Product Portfolio
      • 9.6.4 Business Strategy
      • 9.6.5 Recent Developments
    • 9.7 CSL Limited
      • 9.7.1 Overview
      • 9.7.2 Financials
      • 9.7.3 Product Portfolio
      • 9.7.4 Business Strategy
      • 9.7.5 Recent Developments
    • 9.8 Emergent BioSolutions Inc.
      • 9.8.1 Overview
      • 9.8.2 Financials
      • 9.8.3 Product Portfolio
      • 9.8.4 Business Strategy
      • 9.8.5 Recent Developments
    • 9.9 AstraZeneca
      • 9.9.1 Overview
      • 9.9.2 Financials
      • 9.9.3 Product Portfolio
      • 9.9.4 Business Strategy
      • 9.9.5 Recent Developments
    • 9.10 Bharat Biotech
      • 9.10.1 Overview
      • 9.10.2 Financials
      • 9.10.3 Product Portfolio
      • 9.10.4 Business Strategy
      • 9.10.5 Recent Developments
    • 9.11 Moderna Inc.
      • 9.11.1 Overview
      • 9.11.2 Financials
      • 9.11.3 Product Portfolio
      • 9.11.4 Business Strategy
      • 9.11.5 Recent Developments
    • 9.12 Serum Institute of India Pvt. Ltd.
      • 9.12.1 Overview
      • 9.12.2 Financials
      • 9.12.3 Product Portfolio
      • 9.12.4 Business Strategy
      • 9.12.5 Recent Developments
    • 9.13 Sinovac Biotech Ltd.
      • 9.13.1 Overview
      • 9.13.2 Financials
      • 9.13.3 Product Portfolio
      • 9.13.4 Business Strategy
      • 9.13.5 Recent Developments
    • 9.14 BioNTech SE
      • 9.14.1 Overview
      • 9.14.2 Financials
      • 9.14.3 Product Portfolio
      • 9.14.4 Business Strategy
      • 9.14.5 Recent Developments
    • 9.15 Daiichi Sankyo Company Limited
      • 9.15.1 Overview
      • 9.15.2 Financials
      • 9.15.3 Product Portfolio
      • 9.15.4 Business Strategy
      • 9.15.5 Recent Developments
    • 9.16 Others.
      • 9.16.1 Overview
      • 9.16.2 Financials
      • 9.16.3 Product Portfolio
      • 9.16.4 Business Strategy
      • 9.16.5 Recent Developments
List Of Figures

Figures No 1 to 29

List Of Tables

Tables No 1 to 77

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Sanofi
  • Johnson & Johnson
  • Novartis International AG
  • CSL Limited
  • Emergent BioSolutions Inc.
  • AstraZeneca
  • Bharat Biotech
  • Moderna Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • BioNTech SE
  • Daiichi Sankyo Company Limited
  • Others

FAQs

The key factors driving the Market are Global Immunization Initiatives, Technological Advancements in Vaccine Development, Rising Incidence of Infectious Diseases, Expanding Pediatric Vaccination Programs, Government Support and Funding, Increasing Adoption of Adult Vaccination, Emerging Infectious Disease Threats, Global Health Security Concerns, Increasing Healthcare Expenditure, Population Growth and Urbanization And Improving Vaccine Access in Low-Income Countries.

The “Inactivated Vaccines” category dominated the market in 2022.

The key players in the market are Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc., Sanofi, Johnson & Johnson, Novartis International AG, CSL Limited, Emergent BioSolutions Inc., AstraZeneca, Bharat Biotech, Moderna Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., BioNTech SE, Daiichi Sankyo Company Limited, Others.

“North America” had the largest share in the Preventive Vaccine Market.

The global market is projected to grow at a CAGR of 2% during the forecast period, 2023-2032.

The Preventive Vaccine Market size was valued at USD 88.29 Billion in 2023.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!